These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
191 related articles for article (PubMed ID: 21629038)
1. Enhancer of zeste homolog 2 expression is associated with tumor cell proliferation and invasion in cervical cancer. Fang J; Zhang M; Li Q Am J Med Sci; 2011 Sep; 342(3):198-204. PubMed ID: 21629038 [TBL] [Abstract][Full Text] [Related]
2. MicroRNA-101 exerts tumor-suppressive functions in non-small cell lung cancer through directly targeting enhancer of zeste homolog 2. Zhang JG; Guo JF; Liu DL; Liu Q; Wang JJ J Thorac Oncol; 2011 Apr; 6(4):671-8. PubMed ID: 21270667 [TBL] [Abstract][Full Text] [Related]
3. EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-beta1 and is a predictor of outcome in ovarian carcinoma patients. Rao ZY; Cai MY; Yang GF; He LR; Mai SJ; Hua WF; Liao YJ; Deng HX; Chen YC; Guan XY; Zeng YX; Kung HF; Xie D Carcinogenesis; 2010 Sep; 31(9):1576-83. PubMed ID: 20668008 [TBL] [Abstract][Full Text] [Related]
4. Inhibition of enhancer of zeste homolog 2 (EZH2) expression is associated with decreased tumor cell proliferation, migration, and invasion in endometrial cancer cell lines. Eskander RN; Ji T; Huynh B; Wardeh R; Randall LM; Hoang B Int J Gynecol Cancer; 2013 Jul; 23(6):997-1005. PubMed ID: 23792601 [TBL] [Abstract][Full Text] [Related]
5. Enhancer of zeste homolog 2 expression is associated with tumor cell proliferation and metastasis in gastric cancer. Choi JH; Song YS; Yoon JS; Song KW; Lee YY APMIS; 2010 Mar; 118(3):196-202. PubMed ID: 20132185 [TBL] [Abstract][Full Text] [Related]
6. The polycomb group protein enhancer of zeste 2 is a novel therapeutic target for cervical cancer. Ding M; Zhang H; Li Z; Wang C; Chen J; Shi L; Xu D; Gao Y Clin Exp Pharmacol Physiol; 2015 May; 42(5):458-64. PubMed ID: 25739318 [TBL] [Abstract][Full Text] [Related]
7. Activation of the enhancer of zeste homologue 2 gene by the human papillomavirus E7 oncoprotein. Holland D; Hoppe-Seyler K; Schuller B; Lohrey C; Maroldt J; Dürst M; Hoppe-Seyler F Cancer Res; 2008 Dec; 68(23):9964-72. PubMed ID: 19047178 [TBL] [Abstract][Full Text] [Related]
8. Increased expression of EZH2, a polycomb group protein, in bladder carcinoma. Arisan S; Buyuktuncer ED; Palavan-Unsal N; Caşkurlu T; Cakir OO; Ergenekon E Urol Int; 2005; 75(3):252-7. PubMed ID: 16215315 [TBL] [Abstract][Full Text] [Related]
9. Enhancer of zeste homolog 2 is a novel prognostic biomarker in nonsmall cell lung cancer. Huqun ; Ishikawa R; Zhang J; Miyazawa H; Goto Y; Shimizu Y; Hagiwara K; Koyama N Cancer; 2012 Mar; 118(6):1599-606. PubMed ID: 21837672 [TBL] [Abstract][Full Text] [Related]
10. Enhancer of zeste homolog 2 (EZH2) promotes progression of cholangiocarcinoma cells by regulating cell cycle and apoptosis. Nakagawa S; Okabe H; Sakamoto Y; Hayashi H; Hashimoto D; Yokoyama N; Sakamoto K; Kuroki H; Mima K; Nitta H; Imai K; Chikamoto A; Watanabe M; Beppu T; Baba H Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S667-75. PubMed ID: 23887863 [TBL] [Abstract][Full Text] [Related]
11. The enhancer of zeste homolog 2 gene contributes to cell proliferation and apoptosis resistance in renal cell carcinoma cells. Wagener N; Holland D; Bulkescher J; Crnković-Mertens I; Hoppe-Seyler K; Zentgraf H; Pritsch M; Buse S; Pfitzenmaier J; Haferkamp A; Hohenfellner M; Hoppe-Seyler F Int J Cancer; 2008 Oct; 123(7):1545-50. PubMed ID: 18623083 [TBL] [Abstract][Full Text] [Related]
12. EZH2 silencing by RNA interference inhibits proliferation in bladder cancer cell lines. Zhang YB; Niu HT; Chang JW; Dong GL; Ma XB Eur J Cancer Care (Engl); 2011 Jan; 20(1):106-12. PubMed ID: 20148941 [TBL] [Abstract][Full Text] [Related]
13. Enhancer of zeste homolog 2 promotes the proliferation and invasion of epithelial ovarian cancer cells. Li H; Cai Q; Godwin AK; Zhang R Mol Cancer Res; 2010 Dec; 8(12):1610-8. PubMed ID: 21115743 [TBL] [Abstract][Full Text] [Related]
14. Expression levels of the EZH2 polycomb transcriptional repressor correlate with aggressiveness and invasive potential of bladder carcinomas. Weikert S; Christoph F; Köllermann J; Müller M; Schrader M; Miller K; Krause H Int J Mol Med; 2005 Aug; 16(2):349-53. PubMed ID: 16012774 [TBL] [Abstract][Full Text] [Related]
15. Regulation of pancreatic tumor cell proliferation and chemoresistance by the histone methyltransferase enhancer of zeste homologue 2. Ougolkov AV; Bilim VN; Billadeau DD Clin Cancer Res; 2008 Nov; 14(21):6790-6. PubMed ID: 18980972 [TBL] [Abstract][Full Text] [Related]
16. Aberrant expression of EZH2 is associated with a poor outcome and P53 alteration in squamous cell carcinoma of the esophagus. Yamada A; Fujii S; Daiko H; Nishimura M; Chiba T; Ochiai A Int J Oncol; 2011 Feb; 38(2):345-53. PubMed ID: 21165554 [TBL] [Abstract][Full Text] [Related]
17. Decreased expression of EZH2 is associated with upregulation of ER and favorable outcome to tamoxifen in advanced breast cancer. Reijm EA; Jansen MP; Ruigrok-Ritstier K; van Staveren IL; Look MP; van Gelder ME; Sieuwerts AM; Sleijfer S; Foekens JA; Berns EM Breast Cancer Res Treat; 2011 Jan; 125(2):387-94. PubMed ID: 20306127 [TBL] [Abstract][Full Text] [Related]
18. [Effects of enhancer of zeste homolog (EZH2) downregulation on the proliferation and invasion of nasopharyngeal carcinoma cell and the possible mechanisms]. LIANG BJ; LI XP; LU J; LIN SX; LIU X; LI G; ZHANG B; WANG L; LUO HN; WAN RQ; TIAN WD Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2012 Apr; 47(4):298-304. PubMed ID: 22800347 [TBL] [Abstract][Full Text] [Related]
19. Distinctive expression of the polycomb group proteins Bmi1 polycomb ring finger oncogene and enhancer of zeste homolog 2 in nonsmall cell lung cancers and their clinical and clinicopathologic significance. Kikuchi J; Kinoshita I; Shimizu Y; Kikuchi E; Konishi J; Oizumi S; Kaga K; Matsuno Y; Nishimura M; Dosaka-Akita H Cancer; 2010 Jun; 116(12):3015-24. PubMed ID: 20564407 [TBL] [Abstract][Full Text] [Related]
20. Up-regulation of enhancer of zeste homolog 2 is associated positively with cyclin D1 overexpression and poor clinical outcome in head and neck squamous cell carcinoma. Cao W; Feng Z; Cui Z; Zhang C; Sun Z; Mao L; Chen W Cancer; 2012 Jun; 118(11):2858-71. PubMed ID: 21989926 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]